2seventy bio to Participate in Upcoming Healthcare Conferences

Rhea-AI Summary

2seventy bio (NASDAQ: TSVT) announced its participation in two upcoming investor conferences. The first is the SVB Leerink 10th Annual Global Healthcare Conference on February 16, 2022, at 2:20pm ET, featuring a fireside chat. The second event is the Cowen Virtual 42nd Annual Healthcare Conference on March 7, 2022, at 12:50pm ET, where the company will discuss "Novel Oncology Targets." Live webcasts will be available on 2seventy bio's website, with replays archived for 30 days.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- 2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will present at the following upcoming investor conferences:

• SVB Leerink 10^th Annual Global Healthcare Conference; Fireside chat, Wednesday, February 16, 2022, at 2:20pm ET
• Cowen Virtual 42^nd Annual Healthcare Conference; “Novel Oncology Targets” panel, Monday, March 7, 2022, at 12:50pm ET

Live webcasts of presentations will be available via the Investors and Media section of 2seventy bio’s website at https://ir.2seventybio.com/. A replay of each presentation will be archived on 2seventy bio’s site for 30 days following the event.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: Twitter and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220214005099/en/

Investors:

Elizabeth Pingpank, 860-463-0469

elizabeth.pingpank@2seventybio.com



Media:

Victoria Wagner (von Rinteln), 703-599-2868

victoria.wagner@2seventybio.com



Morgan Adams, 774-313-9852

morgan.adams@2seventybio.com

Source: 2seventy bio, Inc.

FAQ

What conferences will 2seventy bio (TSVT) present at in February 2022?

2seventy bio will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 16, 2022, at 2:20pm ET.

When is 2seventy bio's presentation at the Cowen Virtual Healthcare Conference?

2seventy bio will present at the Cowen Virtual 42nd Annual Healthcare Conference on March 7, 2022, at 12:50pm ET.

How can I watch 2seventy bio's investor conference presentations?

Live webcasts of 2seventy bio's presentations will be available on their website, along with archived replays for 30 days.

What is 2seventy bio's focus in cancer treatment?

2seventy bio focuses on developing novel immuno-oncology therapies aimed at hematologic malignancies and solid tumors.